Urologic Cancer Care
Expert care for prostate, bladder, kidney and other urologic cancers
Urologic cancer (sometimes called genitourinary or GU cancer) includes cancers of the prostate, bladder, kidneys, testicles and other parts of the urinary tract and reproductive system. These cancers can limit your daily life and be difficult to talk about.
An expert team by your side, every step of the way
The MaineHealth urologic cancer team brings together medical oncologists, fellowship-trained urologic oncology surgeons, radiation oncologists and interventional radiologists as one coordinated team focused on your health. We provides the full range of state-of-the-art urologic cancer treatments — surgery, radiation, targeted therapy, immunotherapy and radioligand therapy — right here in Maine.
Recovery from urologic cancer can be a long road. Having trusted care close to home makes that journey easier and supports better health outcomes.
Trust MaineHealth urologic cancer care for:
- Pluvicto (Lu-177 PSMA radioligand therapy) for advanced prostate cancer
- Fellowship-trained urologic oncology surgeons, a specialized subspecialty within urology that focuses on cancer surgery and reconstruction
- Seamless integration with MaineHealth Urology, with care available across our network and subspecialty consultation with the urologic oncology program
- Regular review of your personal care plan by our multidisciplinary tumor review board, where medical oncology, urology, radiation oncology and other specialists meet to monitor your progress together
- Robotic-assisted surgery for prostate, bladder and kidney cancers, using smaller cuts for more precision, less pain and faster recovery
- Minimally invasive treatments for kidney tumors including SBRT, cryoablation and radiofrequency ablation, for people who are not candidates for general surgery
- Active monitoring for people with low-risk prostate and kidney cancers, so we can watch carefully without overtreating
Conditions we treat
Prostate Cancer
- Localized Prostate Cancer
- Advanced and Metastatic Prostate Cancer
- Androgen Pathway Modulator-Resistant Prostate Cancer
Urothelial Carcinoma (Bladder Cancer)
- Non-Muscle Invasive Bladder Cancer (NMIBC)
- Muscle-Invasive Bladder Cancer (MIBC)
- Upper Tract and Lower Tract Urothelial Cancers
- Metastatic Urothelial Carcinoma
Kidney Cancer
- Renal Cell Carcinoma (RCC)
- Non-Clear Cell Renal Cell Carcinoma, Including Papillary and Chromophobe Types
- Other Cell Types and Rare Histologies
Testicular Cancer
- Seminoma
- Non-Seminomatous Germ Cell Tumors (NSGCT)
Urologic Cancer
- Penile and Urethral Cancer
- Bladder Cancer
Screening and prevention
Prostate cancer screening
Prostate cancer screening typically involves a prostate-specific antigen (PSA) blood test, sometimes combined with a digital rectal exam (DRE). Most experts recommend that you talk to your doctor about prostate cancer screening around age 50. If you are African-American or have a family history of prostate cancer, you may need to be screened earlier.
Bladder cancer
There is no routine screening test for bladder cancer. Risk factors include smoking, routine exposure to chemicals and dyes, and chronic bladder infections or irritation. The most common early sign of bladder cancer is blood in your urine, which may be visible to the naked eye or only detected in urine testing. If you have unexplained blood in your urine, talk to your primary care doctor right away.
Kidney cancer
Certain inherited conditions can raise kidney cancer risk, including Birt-Hogg-Dubé (BHD) syndrome, Von Hippel-Lindau (VHL) syndrome, hereditary leiomyomatosis and hereditary papillary renal cancer (HPRCC). Risk factors for kidney cancer include smoking, high blood pressure, obesity and certain inherited syndromes.
Testicular self-exam
Testicular cancer is most common in younger men. A monthly self-exam can help you detect changes early. Look or feel for any lumps, swelling or change in the size or feel of either testicle and talk to your personal doctor about anything you notice.
Genetic testing and hereditary risk
Some urologic cancers are linked to inherited genetic changes, including BRCA2 mutations and Lynch syndrome. If you have personal or family history that raises concern, your personal doctor may refer you for genetic testing.
Diagnosis
Diagnosing a urologic cancer typically begins with blood tests, imaging and tissue sampling. Diagnostic tools include:
- PSA and other blood tests
- Biopsy, a test that takes samples of tissue and studies them for cancer cells.
- Cytoscopy, an examination of the bladder using a thin scope
- Urine cytology, which examines a urine sample under a microscope to check for cancer cells
- Uteroscopy, an examination of the upper urinary tract
- Lymph node biopsy when lymphoma is suspected
- Imaging studies to evaluate the progress of cancer
- Genetic and hereditary testing for inherited conditions, with support from MaineHealth genetic counselors
Treatment
Urologic cancer treatment depends on the specific cancer, its progress, your overall health and your goals. Our team works with you to develop a personal care plan that fits your unique situation. Treatment is reviewed twice a month by our urologic tumor board, where medical oncology, urology, radiation oncology and other specialists develop coordinated care together.
Active monitoring
For some people with low-risk prostate or kidney cancer, the right approach is careful monitoring rather than immediate treatment. Your care team provides regular testing and imaging to watch for changes, with treatment used only when it becomes necessary. This should not feel like “doing nothing” — it is an evidence-based approach that avoids unnecessary side effects and prioritizes your health.
Surgery
Our fellowship-trained urologic oncology surgeons perform every type of cancer surgery, often using robotic-assisted and minimally invasive techniques for greater precision and faster recovery.
- Robotic-assisted radical prostatectomy (RARP) for prostate cancer
- Robotic-assisted radical cystectomy for bladder cancer
- Partial and radical nephrectomy for kidney cancer, often performed minimally invasively
- Retroperitoneal lymph node dissection (RPLND) for testicular cancer
- Urinary reconstruction and diversion when surgical treatment requires it
Radiation therapy
Radiation therapy uses high energy X-rays to destroy cancer cells. For urologic cancers, our radiation oncologists use several advanced approaches:
- External beam radiation therapy (EBRT) for prostate cancer
- Brachytherapy, internal radiation delivered directly to the prostate
- Stereotactic body radiation therapy (SBRT) for prostate cancer and select kidney tumors, a precise approach that delivers higher doses of radiation in fewer treatment sessions
- Bladder-preservation radiation protocols for some bladder cancers
Interventional radiology procedures for kidney tumors
For some kidney tumors, particularly for people who are not good candidates for surgery, interventional radiology offers minimally invasive treatment options:
- Cryoablation, using extreme cold to destroy cancer cells
- Radiofrequency ablation (RFA), using image-guided heat to destroy cancer cells
- Arterial embolization, which blocks blood flow to the tumor
Learn more about interventional radiology
Medical oncology
Medical oncology includes a wide range of systemic treatments, like medications and other therapies that travel through the bloodstream to reach cancer cells throughout the body. Urologic cancer treatment has advanced dramatically over the past decade, with newer therapies extending lives and improving quality of life for many people.
- Hormone therapy and androgen deprivation therapy (ADT) for prostate cancer
- Chemotherapy when appropriate
- Targeted therapies, including VEGF inhibitors for kidney cancer and PARP inhibitors for certain prostate cancers
- Immunotherapy with checkpoint inhibitors for kidney, bladder and other urologic cancers
- BCG therapy, an immune-based treatment given directly into the bladder for non-muscle-invasive bladder cancer
- Bispecific antibody therapies for some advanced cancers
- Antibody-drug conjugates for metastatic urothelial carcinoma
Learn more about medical oncology
Radioligand and radiopharmaceutical therapy
Radioligand therapies attach a small dose of radiation to a molecule that targets cancer cells, delivering treatment directly to the cancer. For advanced prostate cancer, two FDA-approved radioligand therapies are available at MaineHealth:
- Pluvicto (Lu-177 PSMA), for certain advanced prostate cancers
- Radium-223, for prostate cancer that has spread to the bones
Living with urologic cancer
Urologic cancer treatment can involve frequent medical visits over months or years. Managing side effects and quality of life considerations matter during your entire journey.
Our team works closely with the MaineHealth Cancer Care patient services team to make sure you always have what you need to support your recovery — patient navigators, social workers, genetic counselors, registered dietitians, support groups, integrative medicine and home health services.